Nurix Therapeutics price target raised to $27 from $26 at RBC Capital

RBC Capital raised the firm’s price target on Nurix Therapeutics (NRIX) to $27 from $26 and keeps an Outperform rating on the shares. The company’s Q4 messaging was largely consistent with NX-5948’s CLL – chronic lymphocytic leukemia – registrational trial start and clinical updates in CLL/NHL highlighted as key events for 2025, the analyst tells investors in a research note. The potential nomination of the STAT6 development candidate in the first half of 2025, clinical advancement of GS-6791/IRAK4 in 2025, and the R&D day in Q2/mid-2025 may also be “meaningful catalysts”, the firm added.